CBG, or cannabigerol, shows genuine anti-inflammatory activity in lab and animal studies, with early human data pointing in the same direction. It works through several biological pathways that directly tamp down inflammatory signals in the body. But the honest picture is more nuanced than supplement marketing suggests: most of the evidence comes from cell cultures and rodent models, and large-scale human trials are still catching up.
How CBG Reduces Inflammation
CBG interacts with a surprisingly wide range of receptors in the body. It binds to CB2 receptors in the immune system, which trigger immunosuppressive effects that lower levels of TNF-alpha, a protein that drives inflammation in conditions from arthritis to Crohn’s disease. It also activates a receptor called PPARγ, which helps regulate inflammatory gene expression, and interacts with serotonin receptors and pain-sensing channels.
The downstream effects of these interactions are where things get interesting. In a rat model of collagen-induced arthritis, CBG treatment significantly reduced blood levels of two key inflammatory proteins: TNF-alpha and IL-1β. It also suppressed NF-κB, a master switch that controls the expression of dozens of inflammatory genes. When NF-κB activity drops, the entire cascade of inflammation slows. CBG appears to interrupt this cascade at multiple points rather than targeting a single mechanism, which may explain why it shows effects across different types of inflammatory conditions.
Gut Inflammation
Some of the most promising animal data involves inflammatory bowel disease. In a mouse model of colitis, daily treatment with a high-CBG hemp extract dramatically reduced disease severity. Researchers saw increased colon length (a sign of less tissue damage and swelling), lower disease activity scores, and decreased colon tissue damage on microscopic examination. Metabolomic analysis of the mice’s stool also showed normalization of several metabolic pathways tied to inflammation, suggesting CBG was shifting the gut environment back toward a healthier baseline rather than just masking symptoms.
Brain and Nerve Protection
CBG’s anti-inflammatory properties extend to the brain. In models of Huntington’s disease, CBG significantly decreased neuronal death and lowered levels of several pro-inflammatory mediators, including COX-2, TNF-alpha, and IL-6. Treated animals also showed improved motor performance. In Alzheimer’s disease models, CBG reduced neuroinflammation and protected against amyloid-beta toxicity, the protein clumps that damage brain cells. It also enhanced cellular antioxidant defenses and preserved the energy-producing structures inside neurons.
In a lab model simulating stroke-like oxygen deprivation, CBG reduced the release of IL-6 and markers of cell damage from brain support cells called astrocytes. It also diminished DNA damage markers, suggesting protective effects that go beyond simply reducing swelling. In ALS models, CBG suppressed the NF-κB inflammatory pathway while boosting anti-inflammatory signals like IL-10 and IL-37.
Topical Use for Skin Inflammation
For people dealing with red, irritated skin, topical CBG has some of the only human clinical data available. A single-blind study of 20 healthy volunteers found that a 0.1% CBG serum reduced inflammation and redness while improving skin barrier function, performing significantly better than placebo. Lab testing on human skin cells showed CBG had strong antioxidant and anti-inflammatory properties, with activity equal to or better than CBD in those same cell types. This makes topical CBG one of the few applications where there’s at least preliminary human evidence backing the claims.
How CBG Compares to CBD
CBG and CBD are often discussed together, and their anti-inflammatory effects appear to be broadly similar in potency. In a lung inflammation study, both cannabinoids reduced the recruitment of immune cells (neutrophils) by 50 to 65 percent at higher doses. One critical finding from that research: the delivery method mattered enormously. When CBG and CBD were formulated in standard MCT oil, neither showed significant anti-inflammatory effects. Only when formulated with a different carrier did they become effective. This suggests that how you take CBG may matter as much as the dose.
Interestingly, combining CBG and CBD in a 1:1 ratio did not improve results over either one alone in that study, which challenges the popular “entourage effect” marketing claim for combination products. The researchers concluded that both cannabinoids have real anti-inflammatory activity but that formulation is critical to delivering an effective dose.
Where the Human Evidence Stands
The biggest gap in the CBG story is rigorous human clinical data. A completed trial tested 50 mg of full-spectrum CBG oil daily for 8 weeks in 100 healthy adults, measuring standard inflammation markers in the blood including high-sensitivity C-reactive protein and erythrocyte sedimentation rate. Results from this trial have not yet been widely published, but its completion signals that formal human research is actively underway.
No cannabis-derived product, including CBG, has been approved by the FDA for treating any disease. The agency has issued warning letters to companies making therapeutic claims about cannabis-derived products, and it considers any product marketed for medical use to be a drug subject to approval requirements. CBG supplements sold today are not evaluated for safety or effectiveness the way prescription medications are.
Safety Considerations
CBG is generally well tolerated at the doses found in most supplements, but there are cautions worth knowing. Reports of adverse effects on liver structure and function at high doses have raised questions about its safety profile with prolonged use. CBG also inhibits platelet aggregation, the clumping process that helps blood clot, which could be relevant if you take blood thinners or have a bleeding disorder.
There are also concerns about blood pressure interactions. CBG may cause unpredictable changes in blood pressure and could interact with cardiovascular medications. No established safe dosage range exists in human research, which means the doses listed on supplement labels are based on manufacturer decisions rather than clinical evidence. Starting low and paying attention to how your body responds is a reasonable approach, particularly if you take other medications.